Reuters logo
4 months ago
BRIEF-Ab Science announces that masitinib passed its non-futility test at 2 years
March 29, 2017 / 5:19 PM / 4 months ago

BRIEF-Ab Science announces that masitinib passed its non-futility test at 2 years

1 Min Read

March 29 (Reuters) - Ab Science SA:

* Announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

* Interim results will be available in Q2 2018. Final results will be available in Q2 2019

* Study enrolled 600 evaluable patients as planned. Study is therefore now closed to patient enrolment

* Next step for this study is interim analysis expected with 50 pct of patients having reached 96 week treatment duration period Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below